Decision letter for "Beta 1 adrenoceptor blockade promotes angiogenesis in hypertrophied myocardium of transverse aortic constricted mice"

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Sang-Hoon Seol ◽  
Ki-Hun Kim ◽  
Jino Park ◽  
Yeo-Jeong Song ◽  
Dong-Kie Kim ◽  
...  

AbstractHypertrophic cardiomyopathy (HCM) is associated with an increased incidence of Wolff–Parkinson–White (WPW) syndrome and atrial fibrillation. However, a delta-like wide QRS can be observed in the hypertrophied myocardium. When considering the rarity of the paraseptal bypass tract (BT), the normal QRS axis suggests a higher possibility of HCM origin. Otherwise, there is no known electrocardiographic clue indicating a wide QRS differentiation between HCM and WPW syndrome. Moreover, the atriofascicular, nodofascicular/ventricular or fasciculoventricular BT should be differentiated. In this case, atrioventricular conduction system incidental injury revealed a wide QRS origin from the HCM, but this method should be avoided except in some selected cases.


2005 ◽  
Vol 27 (1) ◽  
pp. 111-116 ◽  
Author(s):  
E KEVELAITIS ◽  
A QURESHI ◽  
C MOUAS ◽  
F MAROTTE ◽  
S KEVELAITIENE ◽  
...  

1978 ◽  
Vol 19 (4) ◽  
pp. 579-580
Author(s):  
Kikuko IMAMURA ◽  
Keishiro KAWAMURA ◽  
Tadasu TAKATSU ◽  
Chujiro KASHII

Acta Naturae ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 40-51
Author(s):  
A. G. Ovchinnikov ◽  
T. I. Arefieva ◽  
A. V. Potekhina ◽  
A. Yu. Filatova ◽  
F. T. Ageev ◽  
...  

Heart failure withpreserved ejection fraction (HFpEF) is a severe disease with an often unfavorable outcome. The prevalence of HFpEF continues to increase, while effective treatment options remain elusive. All the medical strategies used toimprove the outcome in a heart failure with reduced ejection fraction proved ineffective in HFpEF, which was probably due to the different mechanisms ofdevelopment of these two types of heart failure and the diversity of the HFpEF phenotypes. According to the current paradigm of HFpEF development, a chronic mild pro-inflammatory statecauses a coronary microvascular endothelial inflammation, with further myocardial fibrosis and diastolic dysfunction progression. This inflammatory paradigm of HFpEF has been confirmed with someevidence, and suppressing the inflammation may become a novel strategy for treating and managing HFpEF. This review summarizes current concepts about a microvascular inflammation in hypertrophied myocardium and provides a translational perspective of the anti-inflammatory and immunomodulatory approaches in HFpEF.


1987 ◽  
Vol 93 (5) ◽  
pp. 741-754 ◽  
Author(s):  
Kenneth G. Warner ◽  
Shukri F. Khuri ◽  
Robert A. Kloner ◽  
Miguel Josa ◽  
Karen M. Dalecki-Chipperfield ◽  
...  

1981 ◽  
Vol 81 (6) ◽  
pp. 865-872 ◽  
Author(s):  
James D. Sink ◽  
Gary L. Pellom ◽  
William D. Currie ◽  
Ronald C. Hill ◽  
Craig O. Olsen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document